EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL

被引：0

作者：

Gettinger, Scott ^{[1
]}

Horn, Leora ^{[2
]}

Antonia, Scott J. ^{[3
]}

Spigel, David R. ^{[4
]}

Gandhi, Leena ^{[5
]}

Sequist, Lecia V. ^{[6
]}

Sankar, Vindira ^{[7
]}

Ahlers, Christoph M. ^{[7
]}

Wigginton, Jon M. ^{[7
]}

Kollia, Georgia ^{[7
]}

Gupta, Ashok ^{[7
]}

Brahmer, Julie R. ^{[8
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Bristol Myers Squibb Co, New York, NY 10154 USA

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

programmed death-1 receptor; nivolumab; NSCLC; subpopulations;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.11-038

引用

页码：S909 / S909

页数：1

共 50 条

[21] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
Hamanishi, Junzo
Mandai, Masaki
Ikeda, Takafumi
Minami, Manabu
Kawaguchi, Atsushi
Matsumura, Noriomi
Abiko, Kaoru
Baba, Tsukasa
Yamaguchi, Ken
Ueda, Akihiko
Kanai, Masashi
Mori, Yukiko
Matsumoto, Shigemi
Murayama, Toshinori
Chikuma, Shunsuke
Morita, Satoshi
Yokode, Masayuki
Shimizu, Akira
Honjo, Tasuku
Konishi, Ikuo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC)
Amin, A.
Plimack, E. R.
Infante, J. R.
Ernstoff, M. S.
Rini, B.
Mcdermott, D. F.
Knox, J.
Pal, S. K.
Voss, M. H.
Sharma, P.
Kollmannsberger, C.
Heng, D. Y. C.
Spratlin, J.
Shen, Y.
Kurland, J. F.
Gagnier, P.
Hammers, H.
BJU INTERNATIONAL, 2014, 114 : 2 - 2
[23] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
Callahan, Margaret K.
Horak, Christine E.
Curran, Michael A.
Hollman, Travis
Schaer, David A.
Yuan, Jianda
Lesokhin, Alexander M.
Kitano, Shigehisa
Hong, Quan
Ariyan, Charlotte Eielson
Busam, Klaus J.
Feely, William
Jure-Kunkel, Maria
Grosso, Joseph
Simon, Jason S.
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok Kumar
Sznol, Mario
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[24] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
Antonia, Scott Joseph
Gettinger, Scott N.
Chow, Laura Quan Man
Juergens, Rosalyn A.
Borghaei, Hossein
Shen, Yun
Harbison, Christopher
Chen, Allen C.
Ready, Neal
Rizvi, Naiyer A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
Michael A Postow
Diana M Cardona
Janis M Taube
Robert A Anders
Clive R Taylor
Jedd D Wolchok
Margaret K Callahan
Michael A Curran
Alexander M Lesokhin
Joseph F Grosso
Christine E Horak
John Cogswell
Jason S Simon
Ashok K Gupta
Mario Sznol
Journal of Translational Medicine, 12 (Suppl 1)
[26] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
Topalian, Suzanne Louise
Sznol, Mario
Brahmer, Julie R.
McDermott, David F.
Smith, David C.
Gettinger, Scott N.
Taube, Janis M.
Drake, Charles G.
Pardoll, Drew M.
Powderly, John D.
Carvajal, Richard D.
Sosman, Jeffrey Alan
Atkins, Michael B.
Antonia, Scott J.
Spigel, David R.
Lawrence, Donald P.
Kollia, Georgia
Gupta, Ashok Kumar
Wigginton, Jon M.
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[27] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
Wolchok, Jedd D.
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Reed, Kathleen
Burke, Matthew M.
Caldwell, Anne
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Horak, Christine E.
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok Kumar
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amin, Asim
Plimack, Elizabeth R.
Infante, Jeffrey R.
Ernstoff, Marc S.
Rini, Brian I.
McDermott, David F.
Knox, Jennifer J.
Pal, Sumanta Kumar
Voss, Martin Henner
Sharma, Padmanee
Kollmannsberger, Christian K.
Heng, Daniel Yick Chin
Spratlin, Jennifer L.
Shen, Yun
Kurland, John F.
Gagnier, Paul
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[29] First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
Gettinger, Scott N.
Shepherd, Frances A.
Antonia, Scott Joseph
Brahmer, Julie R.
Chow, Laura Quan Man
Juergens, Rosalyn A.
Borghaei, Hossein
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Rizvi, Naiyer A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
Motzer, R. J.
Bono, P.
Tomita, Y.
Ravaud, A.
Waxman, I.
Gore, M. E.
BJU INTERNATIONAL, 2013, 112 : 10 - 10

← 1 2 3 4 5 →